PVR and urinary bladder cancer: Anti-CD3 antibody was chemically conjugated with anti-CD155 antibody to synthesis the anti-CD3 × anti-CD155 bispecific antibody (CD155Bi-Ab), with anti-CD155 antibody recognized the bladder cancer cells and anti-CD3 antibody recognized the T cells.